Changeflow GovPing Healthcare & Life Sciences Phase 3 IVIG Trial for Stiff Person Syndrome Ad...
Routine Notice Added Final

Phase 3 IVIG Trial for Stiff Person Syndrome Adults

Email

Summary

A Phase 3 clinical trial evaluating intravenous immunoglobulin (IVIG) as a treatment for Stiff Person Syndrome in adult patients is registered on ClinicalTrials.gov under the identifier NCT07552987. The trial is listed by start date in the registry and presents summary registration details including intervention type, study phase, and condition. No new compliance obligations or regulatory actions are imposed by this registry entry.

Published by NIH on clinicaltrials.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors ClinicalTrials.gov - Phase 3 Trials by Start Date for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 21 changes logged to date.

What changed

This registry entry announces a Phase 3 clinical trial for intravenous immunoglobulin (IVIG) in the treatment of Stiff Person Syndrome in adult patients, posted on ClinicalTrials.gov. The entry provides standard trial registration metadata including the NCT identifier NCT07552987, intervention details, and study phase classification.

Pharmaceutical sponsors, clinical investigators, and healthcare providers involved in rare neurological disease research may find this trial relevant for competitive intelligence and patient referral purposes. The trial registration does not itself impose compliance obligations but reflects ongoing regulatory activity in the rare disease space.

Archived snapshot

Apr 28, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Show glossary

Get daily alerts for ClinicalTrials.gov - Phase 3 Trials by Start Date

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Clinical investigators Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial registration Drug development Rare disease research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Topics
Healthcare Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov - Phase 3 Trials by Start Date publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!